These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15971636)

  • 21. Factors in antipsychotic drug selection: tolerability considerations.
    Nasrallah HA
    CNS Spectr; 2003 Nov; 8(11 Suppl 2):23-5. PubMed ID: 14978455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].
    Ruetsch O; Viala A; Bardou H; Martin P; Vacheron MN
    Encephale; 2005; 31(4 Pt 1):507-16. PubMed ID: 16389718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dyslipidemia and schizophrenia].
    Wetterling T; Schneider B; Weber B
    Psychiatr Prax; 2007 Jul; 34(5):223-9. PubMed ID: 17160750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of atypical antipsychotics on weight and serum lipid levels.
    Meyer JM
    J Clin Psychiatry; 2001; 62 Suppl 27():27-34; discussion 40-1. PubMed ID: 11806486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
    Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
    Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
    Henderson DC; Cagliero E; Gray C; Nasrallah RA; Hayden DL; Schoenfeld DA; Goff DC
    Am J Psychiatry; 2000 Jun; 157(6):975-81. PubMed ID: 10831479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atypical antipsychotics and diabetes mellitus.
    Schwenkreis P; Assion HJ
    World J Biol Psychiatry; 2004 Apr; 5(2):73-82. PubMed ID: 15179666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Metabolic testing rates after initiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers].
    Verdoux H; Gaudron Y; Auleley GR; Deligne J; Blum-Boisgard C; Thiébaut A; Tournier M
    Encephale; 2013 May; 39 Suppl 1():S22-8. PubMed ID: 23246328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
    Meyer JM
    J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists.
    Newcomer JW; Nasrallah HA; Loebel AD
    J Clin Psychopharmacol; 2004 Oct; 24(5 Suppl 1):S1-6. PubMed ID: 15356414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treating the mind and body in schizophrenia: risks and prevention.
    Meyer JM
    CNS Spectr; 2004 Oct; 9(10 Suppl 11):25-33. PubMed ID: 15475874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring for metabolic complications associated with atypical antipsychotics.
    Farver D
    S D J Med; 2005 Feb; 58(2):53-4. PubMed ID: 15756776
    [No Abstract]   [Full Text] [Related]  

  • 37. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.
    Weissman EM; Zhu CW; Schooler NR; Goetz RR; Essock SM
    J Clin Psychiatry; 2006 Sep; 67(9):1323-6. PubMed ID: 17017817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Vigilance level for cardiovascular risk factors in schizophrenic patients].
    Rouillon F; Van Ganse E; Vekhoff P; Arnaud R; Depret-Bixio L; Dillenschneider A
    Encephale; 2015 Feb; 41(1):70-7. PubMed ID: 25637197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse effects of atypical antipsychotics.
    Wirshing DA
    J Clin Psychiatry; 2001; 62 Suppl 21():7-10. PubMed ID: 11584988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.